Product: Vision Science Labs telemedicine platform
Top Line: Vision Science Labs (VSL) has developed a telemedicine platform designed to enable eyecare professionals to provide vision care completely remotely or in-office. The platform features redeveloped digital vision therapy exercises and patent-pending digital vision assessments that are intended to enable doctors, clinicians or therapists to diagnose and treat patients using only a screen and 3D glasses.
Close Up: VSL said that it is “democratizing eyecare by alleviating the three largest challenges facing healthcare: cost, access and quality of care.” Eyecare access currently ranks among the lowest in telemedicine, according to the National Institutes of Health. During the pandemic, ophthalmology and optometry visits declined by over 50 percent, and less than 5 percent of visits were delivered remotely due to poor telemedicine options. VSL said that its technology addresses this by enabling doctors to “frictionlessly” conduct remote patient treatments and assessments as if in-clinic. The technology is designed to remove the need for expensive hardware, increase access and improve the quality of remote eyecare.
Vital Stats: Vision Science Labs said it has “reimagined” traditional vision care, creating a comprehensive catalog of digital vision therapy exercises. Designed to be used by a clinician as an adjunct to care, this tool includes over 90 gamified exercises intended to increase patient compliance. The redeveloped therapies span vergence, tachistoscope, tracking, accommodation, visual processing, reaction timing, acuity and more. Doctors can prescribe a therapy program that can be previewed and adjusted in real time as needed, then utilize analytics to monitor and accelerate their patient’s progress as they advance. The technology’s Vision Assessments feature is intended to allow clinicians to accurately conduct general vision assessments using an internet connection and screens as small as a smartphone, completely removing the need for hardware such as camera, VR headset or eye trackers. VSL said it has been able to accomplish this by developing on-screen stimuli that adjust according to the patient and their personal screen. This technology is patent-pending and is currently undergoing IRB (Institutional Review Board) research for validation. It is expected to be released in the third quarter of 2022.